GlassScriptPhysician profile
Abhijit Kontamwar
NPI 1942473962
$4,639.83
in general payments reported to CMS, 2019-2025
29 companies · $897 in 2025
The $897 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $136 · 2021: $288 · 2022: $777 · 2023: $1,129 · 2024: $761 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,137 · Education: $650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,137.07 |
| Education | $650.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $604.84 | 2023-2025 | Rayaldee |
| Amgen INC. | $505.28 | 2019-2025 | Tavneos, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $460.49 | 2019-2025 | Farxiga |
| Fresenius USA Marketing, INC. | $443.96 | 2019-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $383.24 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $380.61 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $338.04 | 2019-2024 | Jynarque |
| Vifor Pharma, INC. | $203.47 | 2019-2024 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $194.00 | 2019-2024 | Vafseo, Auryxia |
| Bayer Healthcare Pharmaceuticals INC. | $175.68 | 2022-2025 | |
| Horizon Therapeutics Plc | $162.29 | 2019-2022 | |
| Travere Therapeutics, INC. | $131.68 | 2023-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $107.63 | 2023-2025 | Lupkynis |
| Ardelyx, INC. | $80.41 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $66.90 | 2024-2025 | Ultomiris |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $59.65 | 2024-2025 | Keveyis |
| Nxstage Medical, INC. | $53.06 | 2019 | |
| Daiichi Sankyo INC. | $39.06 | 2024-2025 | Injectafer |
| La Jolla Pharmaceutical Company | $38.05 | 2021 | |
| Novo Nordisk INC | $34.09 | 2025 | Ozempic |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $32.11 | 2019-2021 | |
| Chiesi USA, INC. | $32.03 | 2025 | Elfabrio |
| Glaxosmithkline, LLC. | $21.63 | 2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.53 | 2024 | Jardiance |
| Baxter Healthcare | $14.82 | 2024 | Renal - Crrt |
| Genentech USA, INC. | $14.16 | 2019 | |
| Genzyme Corporation | $14.15 | 2019 | |
| Lilly USA, LLC | $14.13 | 2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $12.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abhijit Kontamwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.